Hamid Morovati

Dr. Hamid Morovati

Medical Mycology and Parasitology, Shiraz University of Medical Sciences, Shīrāz, Fārs, Iran
+2
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SNSanam Nami
Sanam Nami
AAAli Aghebati-Maleki
Ali Aghebati-Maleki
HMHamid Morovati
Hamid Morovati
LAleili Aghebati-Maleki
leili Aghebati-Maleki
Invasive candidiasis (IC) can affect individuals with various underlying diseases hospitalized in different parts of hospitals. In recent decades, IC has caused 27-55% mortality in general population. Although Candida albicans (C. albicans) is still the most common cause of IC, non-albicans infections such as C. krusei, C. glabrata, C. lusitaniae, C. tropicalis, and C. parapsilosis have been increased in recent years. Treatment of invasive fungal infections is challenging as the number of existing antifungals is limited and more problems include: toxicity, drug interactions, and drug resistance. These problems provide a clear rationale for the development of new immunotherapies to increase outcomes in patients with invasive fungal infections. Thus, the purpose of this paper is to complete review of the current and modern antifungal drugs in IC therapy and focus on the role of immunotherapy in preventing and controlling the disease. Therefore, we review the features of current research efforts directed towards devising safe and effective immunotherapeutic options for fungal infections, including work on antifungal vaccines, engineered T-cells, cytokines, monoclonal antibodies, and other agents.

1 January 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SNSanam Nami
Sanam Nami
RMRasoul Mohammadi
Rasoul Mohammadi
MVMahshid Vakili
Mahshid Vakili
KKKimia Khezripour
Kimia Khezripour
HMHamed Mirzaei
Hamed Mirzaei
HMHamid Morovati
Hamid Morovati
Fungal infections include a wide range of opportunistic and invasive diseases. Two of four major fatal diseases in patients with human immunodeficiency virus (HIV) infection are related to the fungal infections, cryptococcosis, and pneumocystosis. Disseminated candidiasis and different clinical forms of aspergillosis annually impose expensive medical costs to governments and hospitalized patients and ultimately lead to high mortality rates. Therefore, urgent implementations are necessary to prevent the expansion of these diseases. Designing an effective vaccine is one of the most important approaches in this field. So far, numerous efforts have been carried out in developing an effective vaccine against fungal infections. Some of these challenges engaged in different stages of clinical trials but none of them could be approved by the United States Food and Drug Administration (FDA). Here, in addition to have a comprehensive overview on the data from studied vaccine programs, we will discuss the immunology response against fungal infections. Moreover, it will be attempted to clarify the underlying immune mechanisms of vaccines targeting different fungal infections that are crucial for designing an effective vaccination strategy.

25 May 2022 in Mycoses
Verified
Journal Article
Closed access
NVNarges Vaseghi
Narges Vaseghi
JSJoobin Sharifisooraki
Joobin Sharifisooraki
Hossein KhodadadiHossein Khodadadi
Hossein Khodadadi
SNSanam Nami
Sanam Nami
FSFatemeh Safari
Fatemeh Safari
HMHamid Morovati
Hamid Morovati

11 November 2016 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
ZSZ Saadatpour
Z Saadatpour
ARA Rezaei
A Rezaei
HEH Ebrahimnejad
H Ebrahimnejad
BBB Baghaei
B Baghaei
Geir BjørklundGeir Bjørklund
Geir Bjørklund
HMHamed Mirzaei
Hamed Mirzaei

27 March 2025 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
FAFatemeh Amirinia
Fatemeh Amirinia
AJAhmad Jabrodini
Ahmad Jabrodini
HMHamid Morovati
Hamid Morovati
PAPegah Ardi
Pegah Ardi
MMMarjan Motamedi
Marjan Motamedi
β-glucans area part of the fungal cell wall structure, mainly considered a potential therapeutic and diagnostic tool for invasive fungal infections (IFIs) (1). Several studies have been conducted about their effects on health. They have been reported to reduce blood glucose and have a strong inhibitory effect on lipid peroxidation as a regulator of blood

25 March 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Ehsan AhmadpourEhsan Ahmadpour
Ehsan Ahmadpour
SVSevda Valilou
Sevda Valilou
MGMohammad Ali Ghanizadegan
Mohammad Ali Ghanizadegan
RSRouhollah Seyfi
Rouhollah Seyfi
SHSeyed Abdollah Hosseini
Seyed Abdollah Hosseini
HMHamid Morovati
Hamid Morovati
The epidemiology of Human Immunodeficiency Virus (HIV)-associated pneumocystosis (HAP) is poorly described on a worldwide scale. We searched related databases between January 2000 and December 2022 for studies reporting HAP. Meta-analysis was performed using StatsDirect (version 2.7.9) and STATA (version 17) according to the random-effects model for DerSimonian and Laird method andmetanandmetapropcommands, respectively. Twenty-nine studies with 38554 HIV-positive, 79893 HIV-negative, and 4044 HAP populations were included. The pooled prevalence of HAP was 35.4% (95% CI 23.8 to 47.9). In contrast, the pooled prevalence of PCP among HIV-negative patients was 10.16% (95% CI 2 to 25.3). HIV-positive patients are almost 12 times more susceptible to PCP than the HIV-negative population (OR: 11.710; 95% CI: 5.420 to 25.297). The mortality among HAP patients was 52% higher than non-PCP patients (OR 1.522; 95% CI 0.959 to 2.416). HIV-positive men had a 7% higher chance rate for PCP than women (OR 1.073; 95% CI 0.674 to 1.706). Prophylactic (OR: 6.191; 95% CI: 0.945 to 40.545) and antiretroviral therapy (OR 3.356; 95% CI 0.785 to 14.349) were used in HAP patients six and three times more than HIV-positive PCP-negatives, respectively. The control and management strategies should revise and updated by health policy-makers on a worldwide scale. Finally, for better management and understanding of the epidemiology and characteristics of this coinfection, designing further studies is recommended.